News zum Sektor Gesundheit aus Indien

 

Quadria Capital-backed Maxivision Eye Hospitals Pvt. has begun preparations for an initial public offering, according to people familiar with the matter, as India's healthcare services sector continues to draw investor interest....

Eli Lilly loses share in India's GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy....

The flood of cheap copies of Novo Nordisk A/S' blockbuster drug semaglutide in India is already reshaping the country's fast-growing obesity market, cutting into Eli Lilly & Co.'s early lead and offering a first real test of how Novo may fare as its patents expire worldwide....

India's pharmaceutical exports are thriving, reaching $28.29 billion in April-February FY26, a 5.6% rise despite global challenges. The sector, currently valued at $60 billion, is projected to hit $130 billion by 2030. Leaders are optimistic about continued growth, even with potential US tariff impacts on future exports....

The US has imposed up to 100% tariffs on patented drugs and certain metals, aiming to boost domestic manufacturing. While India's generic drug exports are largely exempt, firms producing branded medicines or inputs for patented drugs may face pressure. Developed nations are expected to bear the brunt of these new measures....

Novo Nordisk India has cut prices of its blockbuster weight-loss and diabetes medications, as an onset of cheaper generic drugs raises competition for the Danish drugmaker in the world's third most overweight country....

Manipal Health Enterprises Pvt. has filed draft papers for an initial public offering, setting the stage for what could be India's largest listing by a hospital operator....

Indian generic drugmakers launch a price war against Novo Nordisk's GLP-1 brands, Ozempic and WeGovy....

At least a dozen large drugmakers are set to roll out copies of Novo Nordisk A/S's blockbuster weight-loss drugs in India, crashing prices as soon as the patent expires Friday....

Paras Healthcare Ltd. has revived plans for an initial public offering and hired three banks for a share sale that could raise as much as $200 million, according to people familiar with the matter....

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions....

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

Indian vaccine developer Bharat Biotech International Ltd. is considering an initial public offering that may raise more than $500 million, according to people familiar with the matter....

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

ZÜRICH/MUMBAI (dpa-AFX) - Der Pharmakonzern Novartis trennt sich von seiner Beteiligung in Indien. Diese Entscheidung folgt auf die im Februar 2024 angekündigte "strategische Überprüfung". Es handelt sich dabei um ......

Für 159 Millionen Dollar verkauft Novartis seine Firmenanteile an ein Konsortium. Der Aktienkurs schnellte nach der Ankündigung in die Höhe....

Um den gesamten Artikel unter onvista.de zu lesen, klicken Sie bitte auf die Überschrift...

Von Kimberley Kao DOW JONES--Ein Konsortium von Private-Equity-Unternehmen unter der Leitung von Waverise Investments kauft einen Mehrheitsanteil von fast 71 Prozent an der indischen Sparte des Pharmariesen Novartis. Der Verkauf wird laut einer Börsenmitteilung ......

Pharma - Novartis verkauft seine indische Tochter für rund 159 Millionen Dollar. Daraufhin schiesst die Aktie von Novartis India um knapp 20 Prozent in die Höhe....